New Therapeutic Agents for the Treatment of COPD and Steroid-Resistant Asthma

COPD is a complex disease combining inTammatory processes and structural changes to lung tissues, affecting more than 10%of theworld population over the age of 40 years. Alveolarmacrophages are known to play a critical role in the pathophysiology of the disease by secreting pro-inTammatory cytokines such as TNF-α and CXCL8. Corticosteroids arewidely-used in the clinic for the treatment of COPD, however their therapeutic beneSt is limited by a steroid-refractory phenotype.1 The objective of the present study was to identify topical dual p38α,γ and HCK kinase inhibitors for the treatment of corticosteroid resistant COPD and asthma.